ATE355829T1 - Einen lipophilen wirkstoff enthaltende feste pharmazeutische zusammensetzung sowie deren herstellung - Google Patents

Einen lipophilen wirkstoff enthaltende feste pharmazeutische zusammensetzung sowie deren herstellung

Info

Publication number
ATE355829T1
ATE355829T1 AT03760779T AT03760779T ATE355829T1 AT E355829 T1 ATE355829 T1 AT E355829T1 AT 03760779 T AT03760779 T AT 03760779T AT 03760779 T AT03760779 T AT 03760779T AT E355829 T1 ATE355829 T1 AT E355829T1
Authority
AT
Austria
Prior art keywords
pharmaceutical composition
solid pharmaceutical
production
active ingredient
composition containing
Prior art date
Application number
AT03760779T
Other languages
English (en)
Inventor
Chacra-Vernet Marie-Line Abou
Noel Zakarian
Dominique Toselli
Rene Gimet
Claude Laruelle
Original Assignee
Cll Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cll Pharma filed Critical Cll Pharma
Application granted granted Critical
Publication of ATE355829T1 publication Critical patent/ATE355829T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT03760779T 2002-06-25 2003-06-24 Einen lipophilen wirkstoff enthaltende feste pharmazeutische zusammensetzung sowie deren herstellung ATE355829T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0207831A FR2841138B1 (fr) 2002-06-25 2002-06-25 Composition pharmaceutique solide contenant un principe actif lipophile, son procede de preparation

Publications (1)

Publication Number Publication Date
ATE355829T1 true ATE355829T1 (de) 2007-03-15

Family

ID=29720010

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03760779T ATE355829T1 (de) 2002-06-25 2003-06-24 Einen lipophilen wirkstoff enthaltende feste pharmazeutische zusammensetzung sowie deren herstellung

Country Status (12)

Country Link
US (1) US20080095838A1 (de)
EP (1) EP1521574B1 (de)
JP (1) JP2005533802A (de)
KR (1) KR20050040869A (de)
AT (1) ATE355829T1 (de)
AU (1) AU2003260621A1 (de)
CA (1) CA2490341A1 (de)
DE (1) DE60312333T2 (de)
ES (1) ES2283821T3 (de)
FR (1) FR2841138B1 (de)
WO (1) WO2004000279A1 (de)
ZA (1) ZA200500716B (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL130602A0 (en) 1999-06-22 2000-06-01 Dexcel Ltd Stable benzimidazole formulation
WO2006096194A2 (en) * 2004-06-17 2006-09-14 Merz Pharma Gmbh & Co. Kgaa Drinkable immediate release tablet made with direct compression of memantine or neramexane
US8367105B2 (en) 2004-11-10 2013-02-05 Teva Pharmaceutical Industries, Ltd. Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby
KR101356335B1 (ko) * 2004-12-06 2014-02-06 릴라이언트 파마슈티컬스 인코퍼레이티드 지질 치료를 위한 오메가-3 지방산 및 이상지질혈증 제제
KR101435199B1 (ko) 2005-05-18 2014-08-28 다이닛본 스미토모 세이야꾸 가부시끼가이샤 드록시도파를 함유하는 안정한 정제
US20070238746A1 (en) 2006-04-06 2007-10-11 Trixi Brandl Thiazolyl-dihydro-chinazoline
US20090074872A1 (en) * 2006-06-26 2009-03-19 Mutual Pharmaceutical Company, Inc. Active Agent Formulations, Methods of Making, and Methods of Use
CA2656277A1 (en) * 2006-06-26 2008-01-03 Mutual Pharmaceutical Company, Inc. Active agent formulations, methods of making, and methods of use
WO2008041553A1 (en) 2006-09-26 2008-04-10 Astellas Pharma Inc. Tacrolimus sustained-release preparation
EP2119442A4 (de) * 2006-12-28 2010-12-15 Astellas Pharma Inc Pharmazeutische zusammensetzung von tacrolimus mit verzögerter freisetzung
WO2009140341A2 (en) * 2008-05-13 2009-11-19 Dr. Reddy's Laboratories Ltd. Atorvastatin compositions
EP2308511B1 (de) * 2008-06-13 2012-12-26 Dainippon Sumitomo Pharma Co., Ltd. In der mundhöhle schnell zerfallende tablette und herstellungsverfahren dafür
US20100159010A1 (en) * 2008-12-24 2010-06-24 Mutual Pharmaceutical Company, Inc. Active Agent Formulations, Methods of Making, and Methods of Use
JP5953646B2 (ja) * 2009-11-24 2016-07-20 大正製薬株式会社 イブプロフェン含有固形製剤
JP5508311B2 (ja) * 2011-02-28 2014-05-28 テバ ファーマシューティカル インダストリーズ リミティド 低水溶性薬物とともに使用することによく適した圧縮固体状投与形態の製造方法およびそれにより製造された圧縮固体状投与形態
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
ES2885523T3 (es) 2011-11-23 2021-12-14 Therapeuticsmd Inc Formulaciones y terapias de reposición hormonal de combinación naturales
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
TR201815994T4 (tr) 2012-09-25 2018-11-21 Chugai Pharmaceutical Co Ltd Ret inhibitörü.
FR2997627B1 (fr) * 2012-11-08 2015-01-16 Hra Pharma Lab Produit de co-micronisation comprenant de l'ulipristal acetate
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
CN106456651A (zh) 2014-04-25 2017-02-22 中外制药株式会社 以高用量含有四环性化合物的制剂
MX2016014281A (es) 2014-05-22 2017-02-22 Therapeuticsmd Inc Formulaciones y terapias de reemplazo de combinación de hormonas naturales.
US11077093B2 (en) 2015-01-16 2021-08-03 Chugai Seiyaku Kabushiki Kaisha Combination drug
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
AU2017239645A1 (en) 2016-04-01 2018-10-18 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
EP3668484B1 (de) 2017-08-17 2022-07-13 F. Hoffmann-La Roche AG Neue pharmazeutische zusammensetzungen für basische oder neutrale niedermolekulare verbindungen
WO2019063478A1 (en) * 2017-09-26 2019-04-04 Capsugel Belgium Nv SUB-MICRONIC PARTICLE FORMULATIONS
EP3815688B1 (de) 2018-06-29 2023-12-06 Chugai Seiyaku Kabushiki Kaisha Pharmazeutische zusammensetzung enthaltend ein schwerlösliches basisches medikament
AU2019337018B2 (en) 2018-09-04 2024-03-07 Chugai Seiyaku Kabushiki Kaisha Method of producing tetracyclic compound
CN114569605B (zh) * 2022-03-10 2024-08-06 沈阳药科大学 阿托伐他汀-黄酮类化合物共无定型复合物及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0729926B2 (ja) * 1989-07-25 1995-04-05 大塚製薬株式会社 易吸収性製剤用組成物
TW209174B (de) * 1991-04-19 1993-07-11 Takeda Pharm Industry Co Ltd
FR2758459B1 (fr) * 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
DE69808670T2 (de) * 1997-12-31 2003-07-03 Choongwae Pharma Corp., Seoul/Soul Herstellungsverfahren und zusammensetzung einer oralen zubereitung von itraconazol
AU3074700A (en) * 1999-01-22 2000-08-07 Yamanouchi Pharmaceutical Co., Ltd. Medicinal compositions with improved oral absorption
US6465011B2 (en) * 1999-05-29 2002-10-15 Abbott Laboratories Formulations comprising lipid-regulating agents
KR100863146B1 (ko) * 2000-07-17 2008-10-14 아스텔라스세이야쿠 가부시키가이샤 경구 흡수 개선 의약 조성물

Also Published As

Publication number Publication date
EP1521574A1 (de) 2005-04-13
FR2841138B1 (fr) 2005-02-25
WO2004000279A1 (fr) 2003-12-31
KR20050040869A (ko) 2005-05-03
CA2490341A1 (fr) 2003-12-31
US20080095838A1 (en) 2008-04-24
DE60312333D1 (de) 2007-04-19
AU2003260621A1 (en) 2004-01-06
ES2283821T3 (es) 2007-11-01
EP1521574B1 (de) 2007-03-07
FR2841138A1 (fr) 2003-12-26
DE60312333T2 (de) 2007-12-20
JP2005533802A (ja) 2005-11-10
ZA200500716B (en) 2006-09-27

Similar Documents

Publication Publication Date Title
ATE355829T1 (de) Einen lipophilen wirkstoff enthaltende feste pharmazeutische zusammensetzung sowie deren herstellung
BR9503386A (pt) Formulaçao farmacêutica comprimido dispersivel e processo para a fabricaçao de comprimidos dispersíveis contendo cloridrato de fluoxetina
BR0211028A (pt) Solução aquosa, método para formação de associações de fármaco e polìmero, composições farmacêuticas, método para formação de uma composição farmacêutica e produto
WO2003090726A3 (en) Chewable soft capsule
EP1428821A8 (de) Piperidin-4-ylamine mit analgetischer Wirksamkeit
ATE544447T1 (de) Arzneistoffcoating mit hohem wirkstoffanteil sowie methoden zu dessen herstellung
AR033548A1 (es) Composicion farmaceutica que comprende un inhibidor de lipasa, un procedimiento para su preparacion, equipo transportable a modo de ''kit'', el uso de dicha composicion en la fabricacion de medicamentos, un inhibidor de lipasa y un secuestrante de acidos biliares
BR0212042A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, e, uso de um composto
EP1281722A4 (de) Hyaluronsäuregel, verfahren zu dessen herstellung sowie das gel enthaltendes medizinisches material
DE60019693D1 (de) Pharmazeutische zusammensetzungen, die wirkstoffabsorptionsfördernde verbindungen enthalten
FR2811552B1 (fr) Composition notamment cosmetique ou pharmaceutique se presentant sous forme solide
WO2005034908A3 (en) A solid dosage form comprising a fibrate and a statin
WO2002022598A8 (en) Quinolinone derivatives as tyrosine kinase inhibitors
EP1291362A4 (de) Komplex aus folsäure und polysacchariden, dessen herstellung sowie diesen komplex als aktiven bestandteil enthaltende pharmazeutische zusammensetzung
ITRM990338A0 (it) Composizione dietetica o farmaceutica utile per la prevenzione o il trattamento dell'iperossaluria.
EP1247456A3 (de) Wohlschmeckende pharmazeutische Zusammensetzung für Haustiere
DE60021749D1 (de) Pharmazeutische formulierung enthaltend tolterodin sowie ihre verwendung
CY1110906T1 (el) Φαρμακευτικη συνθεση για ρινικη χορηγηση φεντανυλης
WO2007000778A3 (en) Modified release pharmaceutical compositions on the basis of two polymers and processes thereof
EP1539122A4 (de) Pharmazeutische wässrige 2,6-diisopropylphenol-zusammensetzungen
DE60211464D1 (de) Pharmazeutische formulierungen mit kontrollierter wirkstoff-freigabe enthaltend milchsäure-polymer, sowie deren herstellung
CA2391076A1 (en) Solutions containing epinastin
IS5851A (is) Ný lyf til inntöku 5-HT4 gerandefna eða mótlyfja
PT1425005E (pt) Composicao farmaceutica que compreende lumiracoxib
BR0211063A (pt) Sais de derivados anticonvulsivantes

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties